<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222647</url>
  </required_header>
  <id_info>
    <org_study_id>VMP-03/2018</org_study_id>
    <secondary_id>2019-002325-30</secondary_id>
    <nct_id>NCT04222647</nct_id>
  </id_info>
  <brief_title>Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA</brief_title>
  <official_title>Prospective, Open-label, Monocenter, Trial to Investigate the Efficacy and Tolerability of WO533, a Lactic Acid Containing Vaginal Suppository, in a Panel of Post-menopausal Women Suffering From Vulvovaginal Atrophy (VVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>proDERM Institut f√ºr Angewandte Dermatologische Forschung GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bremer Pharmacovigilance Service GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy and tolerability of a lactic acid
      containing vaginal suppository with respect to the application in post-menopausal women with
      VVA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VMI</measure>
    <time_frame>Day 1 to 43</time_frame>
    <description>Change of the Vaginal Maturation Index (VMI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>Day 1 to 8, day 8 to 43, and day 1 to 43</time_frame>
    <description>Change of vaginal pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective vulvovaginal atrophy symptoms</measure>
    <time_frame>Day 1 to 8, day 8 to 43, and day 1 to 43</time_frame>
    <description>Change of severity scoring for each of the subjective symptoms (dryness, itching, burning and pain unrelated to sexual intercourse) and as sum score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global judgment of the tolerability by the Investigator</measure>
    <time_frame>Day 1 to 43</time_frame>
    <description>Scoring on a scale from 1 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global judgment of the tolerability by the patient</measure>
    <time_frame>Day 1 to 43</time_frame>
    <description>Scoring on a scale from 1 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 to 43</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>WO533</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation containing WO533 for intravaginal application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WO533</intervention_name>
    <description>Intravaginal application</description>
    <arm_group_label>WO533</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women with subjective symptomatology of vulvovaginal atrophy

          -  Signed written informed consent before participation in the trial

        Exclusion Criteria:

          -  Known hypersensitivity against any of the ingredients of the investigational product

          -  Systemic hormonal replacement therapy, or phytohormonal therapy or use of SERMs within
             3 months before and / or during the conduct of the trial

          -  Local hormonal therapy (vagina/vulva) within 3 months before the trial

          -  If in the opinion of the investigator the patient should not participate in the study
             for any reason
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Christoph Abels, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirstin Deuble-Bente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>proDERM Institute for Applied Dermatological Research, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clarissa Masur, PhD</last_name>
    <phone>+49 521 8808 319</phone>
    <email>clarissa.masur@drwolffgroup.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Hougardy, PhD</last_name>
    <phone>+49 40 839 358 32</phone>
    <email>ahougardy@proderm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>proDERM Institute for Applied Dermatological Research</name>
      <address>
        <city>Schenefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstin Deuble-Bente, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kirstin Deuble-Bente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

